 |
Part 1: Welcome and Introduction
Jorge Cortes, MD
|
 |
Part 2: A Primer on the Clinical Application of Molecular Biomarkers: What to Order and How to Use the Results
Michael W. Kattan, PhD; Katherine A. Hoadley, PhD; Towia A. Libermann, PhD; Mark Sausen, PhD
|
 |
Part 3: Exploring Molecular Pathways in Cancer
Alex A. Adjei, MD, PhD, FACP
|
 |
Part 4: What’s New in Cancer Biomarker Research?
Jerald Radich, MD; Philip C. Mack, PhD
|
 |
Part 5: Innovative Molecular Pathways and Biomarkers in Treating Solid Tumors
Sanjiv S. Agarwala, MD; Mark A. Socinski, MD; Joyce O’Shaughnessy, MD; William M. Grady, MD
|
 |
Part 6: Targeting Genetic Drivers in Premalignancy
Scott M. Lippman, MD
|
 |
Part 7: Case Studies—Innovative Molecular Pathways and Biomarkers in Treating Hematologic Malignancies
Jorge Cortes, MD; A. Keith Stewart, MB ChB; Michael J. Keating, MB, BS; Joseph M. Connors, MD
|
 |
Part 8: An Industry Perspective on the Use of Biomarkers in Cancer: How Are They Really Used?
Roman Yelensky, PhD
|
 |
Part 9: The Impact of Molecular Biomarkers on Clinical Trials
Funda Meric-Bernstam, MD
|
 |
Part 10: Regulatory and Economic Aspects of Precision Medicine
Andrew Stainthorpe, PhD; Michael Kolodziej, MD, FACP
|